SAN DIEGO, March 1, 2016 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company
developing novel clinical-stage therapies for sickle cell disease
and heart failure today announced that the Company's Chief
Executive Officer, Brian M. Culley,
will present at the Cowen and Company 36th Annual Health
Care Conference on Monday, March 7,
2016 at 2:00 p.m. Eastern time
in Salon H at the Boston Marriott Copley Place hotel in
Boston.
Interested parties can access a live audio webcast on the Mast
Therapeutics web site at www.masttherapeutics.com. An archived
presentation will be available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical
company headquartered in San Diego,
California. The Company is developing two clinical-stage
investigational new drugs for serious or life-threatening diseases
and conditions. Vepoloxamer, the Company's lead product candidate,
is in Phase 3 clinical development for the treatment of
vaso-occlusive crisis in patients with sickle cell disease and in
Phase 2 clinical development for the treatment of patients with
heart failure. Enrollment in the Company's 388-patient Phase
3 study of vepoloxamer in patients with sickle cell disease, known
as the EPIC study, was completed in February 2016. Enrollment
in the Company's Phase 2 study of vepoloxamer in patients with
chronic heart failure is ongoing. AIR001, the Company's
second product candidate, is in Phase 2 clinical development for
the treatment of patients with heart failure with preserved
ejection fraction (HFpEF). Enrollment in a Phase 2a study of AIR001
in patients with HFpEF is ongoing and AIR001 was recently selected
by the Heart Failure Clinical Research Network for evaluation in a
100-patient, multicenter, randomized, double-blind,
placebo-controlled, Phase 2 study in patients with HFpEF.
More information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-cowen-and-company-36th-annual-health-care-conference-on-march-7th-300228375.html
SOURCE Mast Therapeutics, Inc.